In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. A, 1996, Pages 1-18

  Baquero, Fernando ^a   Cantón, Rafael ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTION; UNITED STATES;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; QUINOLONES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030012460     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.1.1     Document Type: Article

References (76)

1. Aguiar, J. M., Chacón, J., Cantón, R. & Baquero, F. (1992). The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. Journal of Antimicrobial Chemotherapy 29, 349-50.
2. Alangaden, G. J., Manavahtu, E. K. & Lerner, S. A. (1994). Activity of ciprofloxacin, sparfloxacin and five investigational fluoroquinolones against quinolone-resistant strains of Mycobacterium tuberculosis. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 29.
3. Azoulay-Dupuis, E. Vallee, E., Bedos, J. P. & Pocidalo, J. J. (1990). Efficacy of sparfloxacin (SPFX) in experimental mouse S. pneumoniae models. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990. Abstract 1245, p. 293. American Society for Microbiology, Washington, DC.
4. Barriere, S. L. & Hindler, J. A. (1993). Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Annals of Pharmacotherapy 27, 309-10.
5. Barry, A. L. & Fuchs, P. C. (1991a). Antistaphylococcal activity of the fluoroquinolones CI-960, PD131628, sparfloxacin, ofloxacin and ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 10, 168-71.
6. Barry, A. L. & Fuchs, P. C. (1991b). Multicenter evaluation of in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131638, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 35, 764-6.
7. Bauernfeind, A. (1993). Comparative in-vitro activities of a new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. Journal of Antimicrobial Chemotherapy 31, 505-22.
8. Bourgeois, F. & Bingen, E. (1994). Killing kinetics of five fluoroquinolones against Moraxella catarrhalis at clinical achievable concentrations. Journal of Antimicrobial Chemotherapy 33, 364-5.
9. Brumfitt, W. & Hamilton-Miller, J. M. T. (1993). Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin. Journal of Antimicrobial Chemotherapy 31, 610-12.
10. Bryskier, A. (1995). New fluoroquinolones issued in 1994. Expert Opinion in Investigational Drugs 4, 649-55.
11. Cahana, Z., Gilboa, A. & Raz, R. (1994). Changes in the susceptibility to ciprofloxacin in the community in northern Israel. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 59.
12. Cantón, R., Alvarez, M. E., Alvarez, A., Escobar, H., Suarez, L., Sánchez del Saz, B. et al. (1995). Quinolone resistance in Haemophilus influenzae from cystic fibrosis patients. In Final Programme and Abstract of the Twentieth European Cystic Fibrosis Conference, Brussels, 1995. Abstract P31.
13. Cantón, E., Pemán, J., Jiménez, M. T., Ramón, M. S. & Gobernado, M. (1992). In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrobial Agents and Chemotherapy 36, 558-65.
14. Chin, N. X., Gu, J. W., Yu, K. W., Zhang, Y. X. & Neu, H. C. (1991). In vitro activity of sparfloxacin. Antimicrobial Agents and Chemotherapy 35, 567-71.
15. Clement, J. J., Tanaka, S. K., Alder, J., Vojtko, C., Beyer, J., Hensey, D. et al. (1994). In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 38, 1071-8.
16. Cooper, M. A., Andrews, J. M., Ashby, J. P., Matthews, R. S. & Wise, R. (1990). In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy 26, 667-76.
17. Cormican, M. G. & Jones R. N. (1995). Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory-tract pathogens and β-lactamase producing bacteria. Journal of Antimicrobial Chemotherapy 35, 535-9.
18. Corti, G., Paradisi, F., Giganti, E., Buffini, G., Tortoli, E., Martelli, L. et al. (1995). Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients. Drugs 49, Suppl. 2, 175-6.
19. Crokaert, F., Aoun, M., Duchateau, V., Grenier, P., Rossi, C., Vandermies, A. et al. (1995). In vitro activity of CP-99,219 in comparison with other quinolones. In Proceedings of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, 1995. Abstract 142.
20. Dabernat, H., Delmas, C., Seguy, M. & Lareng, M. B. (1991). Comparative in vitro activity of sparfloxacin against Haemophilus influenzae and Branhamella catarrhalis. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 544-5.
21. Dalhoff, A. (1995). Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Drugs 49, Suppl. 2, 194-6.
22. Decazes, J. M., Casin, I., Kitzis, M. D., Kebbou, M., Vallois, J. M., Geslin, P. et al. (1991). Sparfloxacin and ceftriaxone in the treatment of experimental meningitis due to penicillin-resistant pneumococcus. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 924, p. 253. American Society for Microbiology, Washington, DC.
23. Desnottes, J. F. & Diallo, N. (1994). Effect of sparfloxacin on Staphylococcus aureus adhesiveness and phagocytosis. Journal of Antimicrobial Chemotherapy 33, 737-46.
24. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and gyrB mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
25. Focht, J., Nösner, K. & Kresken, M. (1993). Sensitivity of community- and hospital-acquired bacterial isolates to sparfloxacin in comparison with other antibiotics. Drugs 45, Suppl. 3, 153-6.
26. Forstall, G. J., Knapp, C. C. & Washington, J. A. (1991). Activity of new quinolones against ciprofloxacin resistant staphylococci. Antimicrobial Agents and Chemotherapy 35, 1679-81.
27. Fuchs, P. C., Barry, A. L., Pfaller, M. A., Allen, S. D. & Gerlach, E. H. (1991). Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960 and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 35, 764-6.
28. Gaja, M., Higa, F., Yamashiro, T., Tateyama, M., Owan, I., Nakamoto, A. et al. (1991). In vitro and in vivo antibacterial evaluation of sparfloxacin (AT-4140), a new oral pyridone carboxylic acid derivative against Legionella infection. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 557-8.
29. Hoffmann, S. & Gutschik, E. (1994). Ciprofloxacin in vitro susceptibility of 945 clinical bacterial isolates at two Copenhagen hospitals, 1992. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 5.
30. Ji, B., Truffot-Pernot, C. & Grosset, J. (1991). In vitro and in-vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72, 181-6.
31. Joly-Guillou, M. L. & Bergogne-Bérézin, E. (1992). In vitro activity of sparfloxacin perfloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp. Journal of Antimicrobial Chemotherapy 29, 466-8.
32. Jones, R. N. (1991). Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp. Journal of Antimicrobial Chemotherapy 27, 389-90.
33. Kaku, M., Ishida, K., Kohno, S., Koga, H., Hara, K. & Usui, T. (1994). Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 30.
34. Kenny, G. E. & Cartwright, F. D. (1991). Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrobial Agents and Chemotherapy 35, 587-9.
35. Kobayashi, H. (1994). Effect of sparfloxacin for biofilm bacteria. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 12.
36. Kojima, T., Inoue, M. & Mitsuhashi, S. (1989). In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 33, 1980-8.
37. Kresken, M., Hafner, D., Mittermayer, M., Verbist, L., Bergogne-Bérézin, E., Giamarellou, H. et al. (1994). Prevalence of fluoroquinolone resistance in Europe. Infection 22, Suppl. 2, S90-7.
38. Loo, V. G., Lavellee, J., McAlear, D. & Robson, H. G. (1994). The in-vitro susceptibilities of 326 Streptococcus pneumoniae isolates to nine antimicrobial agents including penicillin and newer quinolones. Journal of Antimicrobial Chemotherapy 33, 641-5.
39. Louie, A., Baltch, A. L., Riutz, W. J. & Smith, R. P. (1991). Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xantomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. Journal of Antimicrobial Chemotherapy 27, 793-9.
40. Loza, E., Cantón, R., Martínez-Beltrán, J., Elia, M. & Baquero, F. (1991). Sparfloxacin activity on Gram-positive bacteria: effect on organisms with PBP-mediated beta-lactam resistance. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 550-3.
41. Malmborg, A. S. & Ahlen, S. (1993). In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory pathogens. Chemotherapy 39, 32-5.
42. Martinez-Beltrán, J., Cantón, R., Alvarez, M., Sierra, M. P., de Rafael, L. & Baquero, F. (1995). Clinafloxacin: comparative in vitro activity against respiratory tract bacterial pathogens. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F181, p. 144. American Society for Microbiology, Washington, DC.
43. Nakamura, S., Minami, A., Nakata, K., Kurobe, N., Kouno, K., Sakaguchi, Y. et al. (1989). In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 33, 1167-73.
44. Nakata, K., Maeda, H. & Fujii, A. (1992). In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 36, 188-90.
45. Nakayama, I. & Vamaji, E. (1994). Antibacterial activity of fluoroquinolones against Pseudomonas aeruginosa isolated from surgical infections. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 38.
46. Ouabedesselam, S., Hooper, D. C., Tankovic, J. & Soussy, C. J. (1995). Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrobial Agents and Chemotherapy 39, 1667-70.
47. Palumbo, M., Gatto, B., Zagoto, G. & Palu, G. (1993). On the mechanism of action of quinolone drugs. Trends in Microbiology 1, 232-5.
48. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs 49, Suppl. 2, 235-7.
49. Pascual, A., García, I., Ramirez, E. & Perea, E. J. (1994). Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FA, 1994. Abstract E47. American Society for Microbiology, Washington, DC.
50. Perea, E. (1995). Main pathogens responsible for community acquired respiratory tract infections: H. influenzae. In Programme of the International Scientific Symposium on Sparfloxacin. Seville, 1995.
51. Piddock, L. J. (1994). New quinolones and Gram positive bacteria. Antimicrobial Agents and Chemotherapy 38, 163-9.
52. Piddock, L. J. V. & Jin, Y. F. (1992). Selection of quinolone-resistant mutants of Haemophilus influenzae and Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 30, 109-10.
53. Prosser, B. L. T. (1994). US multicenter study on the comparative in vitro activity of fleroxacin, ciprofloxacin, ofloxacin and lomefloxacin. In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 7.
54. Rastogi, N. & Goh, K. S. (1991). In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrobial Agents and Chemotherapy 35, 1933-6.
55. Renaudin, H. & Bebear, C. (1992). Activité in vitro de la sparfloxacine sur les mycoplasmes. Pathologie Biologie 40, 450-4.
56. Richard, P. & Gutmann, L. (1992). Sparfloxacin and other new fluoroquinolones. Journal of Antimicrobial Chemotherapy 30, 739-44.
57. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. (1994). In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1402-3.
58. Rohner, P., Peebo, M., Lew, D. P., Auckenthaler, R. & Pechère, J. C. (1992). Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. Journal of Antimicrobial Chemotherapy 29, 41-8.
59. Rolston, K. V. I. H., Messer, M. & Nguyen, H. (1991). Susceptibility of Pseudomonas spp., Xanthomonas maltophilia, Acinetobacter spp. and Alcaligenes dentrificans xylosoxidans to newer quinolones. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 679-83.
60. Rotstein, C., Amsterdam, D., Beam, T. R., Mandell, L. A. & Gorzynski, E. (1993). In vitro activity of sparfloxacin, ciprofloxacin, oflosacin, and other antibiotics against bloodstream isolates of gram-positive cocci. Diagnostic Infectious Diseases 17, 85-91.
61. Saito, H., Tomioka, H. & Sato, K. (1991). Antimycobacterial activity of the new quinolone sparfloxacin. European Journal of Clinical Microbiology and Infectious Diseases Special Issue, 203-12.
62. Sanders, C. C., Sanders, W. E. & Thomson, K. S. (1995). Fluoroquinolone resistance in staphylococci: new challenges. European Journal of Clinical Microbiology and Infectious Diseases 14, Suppl. 1, 6-11.
63. Scorneaux, B., Orfila, J. & Tulkens, P. M. (1991). Comparative activity of sparfloxacin and erythromycin in a model of J774 macrophages infected with Chlamydia pneumoniae. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 511, p. 184. American Society for Microbiology, Washington, DC.
64. Segreti, J. & Connelly, R. (1995). Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period. Drugs 49, Suppl. 2, 185-7.
65. Simor, A. E., Fuller, S. A. & Low, D. E. (1990). Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrobial Agents and Chemotherapy 34, 2283-6.
66. Smith, K. R. & Cobbs, C. G. (1992). In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. European Journal of Clinical Microbiology and Infectious Diseases 11, 55-8.
67. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1992). Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 36, 856-9.
68. Takenouchi, T., Ishii, C., Sugawara, M., Tokue, Y. & Ohya, S. (1995). Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrobial Agents and Chemotherapy 39, 1414-8.
69. Tanaka, M., Zhang, Y. X., Ishida, H. et al. (1994). Mechanisms of quinolone and methicillin resistant Staphylococcus aureus In Proceedings of the Fifth International Symposium on New Quinolones, Singapore, 1994. Abstract 60.
70. Thornsberry, C. (1994). Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection 22, Suppl. 2, 80-9.
71. Trucksis, M., Wolfson, J. S. & Hooper, D. C. (1991). A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. Journal of Bacteriology 173, 5854-60.
72. Verbist, L. & Verhaegen, J. (1990). Comparative in vitro activity of sparfloxacin (AT 4140) against respiratory pathogens. In Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 1990. Abstract 16, p. 89. American Society for Microbiology, Washington, DC.
73. Verbist, L. & Verhaegen, J. (1995). Comparative in vitro activity of BAY Y3118 against selected species. Drugs 49, Suppl. 2, 264-5.
74. Wise, R., Andrews, J. M., Cooper, M. A. & Matthews, R. (1991). The activity of sparfloxacin and other agents against Chlamydia pneumoniae: the effects of pre and post antibiotic exposure. In Program and Abstracts of the Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 680, p. 212. American Society for Microbiology, Washington, DC.
75. Xiao, Y. H., Kitamura, A., Hoshino, K. & Sato, K. (1995). Quinolone resistance mechanisms in Klebsiella pneumoniae. Drugs 49, Suppl. 2, 190-1.
76. Yamane, N. & Jones, R. N. (1991). In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and Gram-positive species resistant to vancomycin. Diagnostic Microbiology and Infectious Diseases 14, 337-45.